TY - JOUR T1 - Prevalence of SARS-CoV-2 among workers returning to Bihar gives snapshot of COVID across India JF - medRxiv DO - 10.1101/2020.06.26.20138545 SP - 2020.06.26.20138545 AU - Anup Malani AU - Manoj Mohanan AU - Chanchal Kumar AU - Jake Kramer AU - Vaidehi Tandel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/28/2020.06.26.20138545.abstract N2 - India has reported the fourth highest number of confirmed SARS-CoV-2 cases worldwide. Because there is little community testing for COVID, this case count is likely an underestimate. When India partially exited from lockdown on May 4, 2020, millions of daily laborers left cities for their rural family homes. RNA testing on a near-random sample of laborers returning to the state of Bihar is used to estimate positive testing rate for COVID across India for a 6-week period immediately following the initial lifting of India’s lockdown. Positive testing rates among returning laborers are only moderately correlated with, and 21% higher than, Indian states’ official reports, which are not based on random sampling. Higher prevalence among returning laborers may also reflect greater COVID spread in crowded poor communities such as slums.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis paper has no outside funding. Jake Kramer is funded by an internal grant from the University of Chicago's Center for Global Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been reviewed by University of Chicago's SBS IRB (IRB20-1110) and has been found exempt.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be requested from the Government of Bihar. ER -